JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2007; 49:311-319, doi:10.1016/j.jacc.2006.08.052
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Acknowledgement and Writing Group
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study

Heart Protection Study Collaborative Group1,*

Heart Protection Study Collaborative Group, Clinical Trial Service Unit, University of Oxford, Oxford, Oxfordshire, United Kingdom.


Figure 1
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Relative Hazard of Vascular Events and Hospitalization or Death Due to HF by Baseline N-BNP Level (Adjusted for Differences in Baseline Characteristics)

N-terminal pro-B-type natriuretic peptide (N-BNP) level is displayed on a log-scale. The area of each plotting symbol is proportional to the amount of statistical information (i.e., number of events); the vertical lines through the points represent 95% confidence intervals (CI). Risk estimates are adjusted for age, gender, prior diseases, baseline drug use, randomization to simvastatin, and major vascular risk factors (see Table 1). A 1-SD increase in measured log N-BNP at baseline is associated with (on average) a 30% (95% CI 25 to 36) increase in the relative risk of major vascular events, a 51% (95% CI 41 to 62) increase in the relative risk of major coronary event, a 23% (95% CI 13 to 34) increase in the relative risk of stroke, and a 3.4-fold (95% CI 2.9 to 3.9) increase in the relative risk of heart failure (HF).

 

Figure 2
View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 Effects of Simvastatin on Vascular Events in Participants Subdivided by Baseline N-BNP Level

CI = confidence interval; N-BNP = N-terminal pro-B-type natriuretic peptide.

 

Figure 3
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3 Absolute Benefits of Simvastatin Allocation on First MVE and First MCE, by Baseline N-BNP Level

Absolute benefits of simvastatin allocation on first major vascular event (MVE) and first major coronary event (MCE) in participants subdivided by baseline N-terminal pro-B-type natriuretic peptide (N-BNP) level. P = placebo; S = simvastatin.

 

Figure 4
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4 Effects of Simvastatin on Vascular and Nonvascular Mortality in Participants Subdivided by Baseline N-BNP Level

CI = confidence interval; N-BNP = N-terminal pro-B-type natriuretic peptide.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.